Clinical trial
An Open-label, Multi-center, Phase 4 Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
NCT04586660 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Multi-center, Phase 4 Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
- Lead sponsor
- Amgen
- Phase
- Phase 4
- Overall status
- Active, not recruiting
- Start date
- August 17, 2023
- Completion date
- March 7, 2028
- Enrollment
- 36 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.